Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $725.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target boosted by The Goldman Sachs Group from $654.00 to $725.00 in a report released on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on VRTX. Jefferies Financial Group raised their price target on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Stifel Nicolaus boosted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a report on Tuesday. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Morgan Stanley initiated coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 1st. They set an “overweight” rating and a $665.00 price objective on the stock. Finally, Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $596.44.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $542.50 on Tuesday. Vertex Pharmaceuticals has a one year low of $406.67 and a one year high of $568.67. The stock has a 50-day moving average of $522.81 and a 200 day moving average of $481.42. The company has a market capitalization of $137.69 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.74 and a current ratio of 2.34.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the firm posted $4.80 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.8% compared to the same quarter last year. On average, sell-side analysts forecast that Vertex Pharmaceuticals will post 16.50 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently made changes to their positions in the business. MADDEN SECURITIES Corp purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $26,000. Meeder Asset Management Inc. bought a new position in Vertex Pharmaceuticals during the second quarter valued at $26,000. Community Financial Services Group LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $26,000. Elevation Wealth Partners LLC grew its position in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $32,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.